Stockreport

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
PDF - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3, and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in [Read more]